Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 108 results for "sarabjit kour nangra"

Neutral rating on Cipla, Sun Pharma no game changer: Sarabjit ...

will add to the company but since the company is so big that such small approvals do not add significantly." In an interview with ET Now, Sarabjit Kour Nangra, VP - Research, Angel Broking, Pharma, shares his views on markets. Excerpts: ET Now: What is that ... Economic Times, 1 week ago

Infosys' topline a positive surprise; revenue growth commendable: Sarabjit Kour Nangra, Angel Broking

In a chat with ET Now, Sarabjit Kour Nangra, Angel Broking, talks about Infosys' latest numbers. Excerpts: ET Now: Prima facie, Infosys' numbers look okay. What is your take? Sarabjit Kour Nangra: Infosys' topline has positively surprised. 4.5% ...
 Economic Times1 month ago

Tech Mahindra and many small caps have indicated trend of lower revenue for Q1: Sarabjit Kour Nangra

"Most of the IT companies have been pointing towards a healthy (revenue filled) full year, which should entail a healthy first quarter."
 Economic Times2 months ago
Financial Express

Dishman Pharma shares gain as company posts robust Q1 net profit figures

Dishman Pharmaceutical & Chemicals reported 58.55 per cent Year-on-Year (YoY) rise in a consolidated net profit figures for the quarter ended June 2015. (Photo: Reuters) Dishman Pharmaceutical & Chemicals shares jumped over 7 per cent intraday on ...
 Financial Express1 day ago Wipro shares fall 4% on Q1 results, experts bullish  Business Today India1 month ago Lupin tumbles over 5% as Q1 Net dips; top loser on Sensex  DNA India1 month ago Infy expensive despite good Q1 show: Expert  Economic Times1 month ago

Aurobindo gets USFDA nod for its Entecavir

Aurobindo Pharma has received the final approval from the US food & drug administration (USFDA) to manufacture and market Entecavir tablets in the strengths of 0.5mg and 1mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference ...
 The Financial Chronicle5 days ago Sun Pharmaceutical Industries Ltd Shares Flare Up on US FDA Nod for Dermatology Drug  MedIndia1 week ago Aurobindo gets USFDA nod for generic ulcer drug  The Financial Chronicle1 week ago Aurobindo Pharma to build three formulation plants in Andhra Pradesh, Telangana  Livemint.com2 weeks ago
Nikkei Asian Review

Ranbaxy a bitter pill for Sun Pharma

NEW DELHI -- India's Sun Pharmaceutical Industries is finding it harder than expected to integrate with former rival, Ranbaxy Laboratories, which it bought from Japan's Daiichi Sankyo for $4 billion in March. Close Dilip Shanghvi Reuters ...
 Nikkei Asian Review5 days ago Analyst views on Sun Pharma warning on Ranbaxy integration charges  MyIris1 month ago

L&T Infotech set to hire top executives ahead of IPO

MUMBAI: Larsen & Toubro is on the prowl to hire a number of senior executives for leadership roles in its IT services arm L&T Infotech ahead of its planned initial public offer (IPO) this year, industry insiders said. The company, which hired former Infosys ...
 Economic Times6 days ago

Lupin gets USFDA nod for anti-cholesterol drug

Chennai: Pharmaceutical major Lupin Ltd on Thursday said it has got the USFDA approval for anti-cholesterol tablet though a sector analyst said the drug may not contribute to the company's financials majorly. Lupin, in a statement, said it has ...
 India Online.in1 week ago 'US nod to Lupin's anti-cholesterol drug may not fatten up firm financials'  Prokerala1 week ago USFDA Approved Lupin's Anti-Cholesterol Drug may Not Fatten Up Firm Financials  Med India1 week ago Lupin gets US FDA approval for anti-diabetes drug  Business Standard India1 month ago
Money Today

Sun Pharma shares close 3% higher on Q1 earnings

ne Bureau Mumbai Last Updated: August 12, 2015 | 17:43 IST Sun Pharmaceuticals had on Tuesday reported 60 per cent dip in consolidated net profit to Rs 478.96 crore for the quarter ended June 30, pulled down by impairment charges and expense of Rs 685.17 ...
 Money Today2 weeks ago Aurobindo Pharma gets USFDA approval for Azithromycin, shares up  Money Today2 months ago

IT majors witness sustantial growth in quarterly revenue

Profit growth seemed to have taken a backseat for IT majors during the first quarter of this financial year. Most of the top companies reported muted or negative operating profit growth. However, net profit growth was higher because of increases in currency ...
 The Financial Chronicle1 month ago Traditional business and growth in US pulls Q1 numbers for IT giants  Smart Investor1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sarabjit kour nangra
Get updated on latest news & your favorite topics right in your inbox!
More     Less